These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27561197)

  • 21. Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival.
    Merchant FM; Desai Y; Addish MA; Kelly K; Casey M; Goyal A; Leon AR; El-Chami MF
    Tex Heart Inst J; 2018 Aug; 45(4):221-225. PubMed ID: 30374229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current aspects of defibrillator therapy in congestive heart failure].
    Trappe HJ; Meine M; Pfitzner P; Voigt B; Weismüller P
    Z Kardiol; 2001; 90 Suppl 1():28-34. PubMed ID: 11261337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
    Pun PH; Hellkamp AS; Sanders GD; Middleton JP; Hammill SC; Al-Khalidi HR; Curtis LH; Fonarow GC; Al-Khatib SM
    Nephrol Dial Transplant; 2015 May; 30(5):829-35. PubMed ID: 25404241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
    Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
    N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
    Poole JE; Olshansky B; Mark DB; Anderson J; Johnson G; Hellkamp AS; Davidson-Ray L; Fishbein DP; Boineau RE; Anstrom KJ; Reinhall PG; Packer DL; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2020 Jul; 76(4):405-415. PubMed ID: 32703511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Cheyne-Stokes respiration reduces arrhythmic events in chronic heart failure.
    Bitter T; Gutleben KJ; Nölker G; Westerheide N; Prinz C; Dimitriadis Z; Horstkotte D; Vogt J; Oldenburg O
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1132-40. PubMed ID: 23844935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients.
    Zhang Y; Guallar E; Blasco-Colmenares E; Butcher B; Norgard S; Nauffal V; Marine JE; Eldadah Z; Dickfeld T; Ellenbogen KA; Tomaselli GF; Cheng A
    J Am Coll Cardiol; 2015 Aug; 66(5):524-31. PubMed ID: 26227190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
    Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
    Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy.
    Akoudad S; Dabiri Abkenari L; Schaer BA; Sticherling C; Levy WC; Jordaens L; Theuns DA
    Am J Cardiol; 2017 May; 119(9):1414-1420. PubMed ID: 28267958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biventricular stimulation therapy in patients with heart failure and tachycardic arrhythmias. Indications--results--prospects].
    Trappe HJ
    Biomed Tech (Berl); 2002 Oct; 47(9-10):243-9. PubMed ID: 12369212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow up of patients with implantable cardioverter-defibrillators and mild, moderate, or severe impairment of left ventricular function.
    Trappe HJ; Wenzlaff P; Pfitzner P; Fieguth HG
    Heart; 1997 Sep; 78(3):243-9. PubMed ID: 9391285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator--the EVADEF study.
    Marijon E; Trinquart L; Otmani A; Leclercq C; Fauchier L; Chevalier P; Klug D; Defaye P; Lellouche N; Mansourati J; Deharo JC; Sadoul N; Anselme F; Maury P; Davy JM; Extramiana F; Hidden-Lucet F; Probst V; Bordachar P; Mansour H; Chauvin M; Jouven X; Lavergne T; Chatellier G; Le Heuzey JY;
    Am Heart J; 2010 Apr; 159(4):659-664.e1. PubMed ID: 20362726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis.
    Sun WP; Li CL; Guo JC; Zhang LX; Liu R; Zhang HB; Zhang L
    Heart Fail Rev; 2016 Jul; 21(4):447-53. PubMed ID: 27043219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implantable cardioverter/defibrillator interventions in primary prevention: do current implantation criteria really predict ICD interventions?
    Cools T; Rossenbacker T; Floré V; Nuyens D; Heidbochel H; Willems R
    Acta Cardiol; 2011 Apr; 66(2):145-51. PubMed ID: 21591571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated electrocardiographic quantification of myocardial scar in patients undergoing primary prevention implantable cardioverter-defibrillator implantation: Association with mortality and subsequent appropriate and inappropriate therapies.
    Reichlin T; Asatryan B; Vos MA; Willems R; Huikuri HV; Junttila MJ; Schlögl SC; Hnatkova K; Schaer BA; Malik M; Zabel M; Sticherling C;
    Heart Rhythm; 2020 Oct; 17(10):1664-1671. PubMed ID: 32428669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention.
    Ascoeta MS; Marijon E; Defaye P; Klug D; Beganton F; Perier MC; Gras D; Algalarrondo V; Deharo JC; Leclercq C; Fauchier L; Babuty D; Bordachar P; Sadoul N; Boveda S; Piot O;
    Heart Rhythm; 2016 May; 13(5):1045-1051. PubMed ID: 26749313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.